




## RESEARCH ARTICLE

# Metformin improves FOXP3 mRNA expression through suppression of interferon gamma levels in pristane-induced murine models of lupus [version 1; peer review: 1 approved with reservations]

Stevent Sumantri<sup>1</sup> , Mochammad Hatta<sup>2</sup>, Rosdiana Natzir<sup>3</sup>, Haerani Rasyid<sup>4</sup>, Iris Rengganis<sup>5</sup>, Muhammad Nasrum Massi<sup>2</sup>, Andi Asadul Islam<sup>6</sup>, Gatot Lawrence<sup>7</sup>, Ilhamjaya Patellongi<sup>8</sup>, Andi Fachruddin Benyamin<sup>4</sup>

<sup>1</sup>Department of Internal Medicine, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia

<sup>2</sup>Department of Microbiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

<sup>3</sup>Department of Biochemistry, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

<sup>4</sup>Department of Internal Medicine, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

<sup>5</sup>Department of Internal Medicine, Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia

<sup>6</sup>Department of Surgery, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

<sup>7</sup>Department of Pathological Anatomy, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

<sup>8</sup>Department of Physiology, Universitas Hasanuddin, Makassar, Sulawesi Selatan, Indonesia

**V1** First published: 11 May 2020, 9:342  
<https://doi.org/10.12688/f1000research.23471.1>  
 Latest published: 11 May 2020, 9:342  
<https://doi.org/10.12688/f1000research.23471.1>

## Abstract

**Background:** A recent study has indicated the potential of metformin therapy for lupus in animal models, but there has been no study evaluating the effect on pristane-induced lupus. This study aims to evaluate the effect of intraperitoneal versus oral metformin on interferon (IFN)- $\gamma$  levels and FOXP3 mRNA expression on pristane-induced female BALB/c mice.

**Methods:** In total, 31 female BALB/c mice, aged 6 weeks, were intraperitoneally induced with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane). After 120 days, the mice were grouped and treated with various treatments: normal saline 100 mcl, oral metformin 100mg/kgBW, or intraperitoneal metformin 100mg/kgBW. After 60 days of treatment, all treatment groups were sacrificed, and kidney specimens prepared and stained using hematoxylin and eosin.

**Results:** IFN $\gamma$  levels of saline controls vs. oral metformin group was 309.39 vs. 292.83 pg/mL (mean difference 16.56 pg/mL; 95% CI 0.74-32.37;  $p=0.042$ ), and saline control vs. intraperitoneal metformin group was 309.39 vs. 266.90 pg/mL (mean difference 42.49 pg/mL; 95% CI 29.24-55.73 pg/mL;  $p<0.004$ ). FOXP3 mRNA expression changes in saline controls vs. oral metformin group was 6.90 vs. 7.79-

## Open Peer Review

### Reviewer Status ?

Invited Reviewers

1

### version 1

11 May 2020

?

report

1. **Shuang Ye**, Shanghai Jiaotong University  
 School of Medicine, Shanghai, China

Any reports and responses or comments on the article can be found at the end of the article.

fold change (mean difference -0.89-fold change; 95% CI -1.68(-0.11);  $p=0.03$ ) and in saline controls vs. intraperitoneal metformin group was 6.90 vs. 9.02-fold change (mean difference -2.12-fold change; 95% CI -2.99(-1.25);  $p<0.001$ ). Correlation analysis of FOXP3 mRNA expression and IFN $\gamma$  level changes revealed a Pearson correlation of -0.785 ( $p=0.001$ ) and R2 value of 0.616 ( $p=0.001$ ).

**Conclusion:** Metformin is a potential new therapy to reduce the levels of IFN $\gamma$  and increase FOXP3 mRNA expression in mice models of systemic lupus erythematosus. Intraperitoneal metformin, i.e intravenous administration in human, could provide a novel route of administration to improve the effect of metformin for lupus patients.

### Keywords

systemic lupus erythematosus, pristane induced lupus, oral metformin, intraperitoneal metformin, AMPK/mTOR pathway

**Corresponding author:** Stevent Sumantri ([stevent.sumantri@uph.edu](mailto:stevent.sumantri@uph.edu))

**Author roles:** **Sumantri S:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; **Hatta M:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Natzir R:** Conceptualization, Investigation, Methodology, Supervision, Writing – Review & Editing; **Rasyid H:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Rengganis I:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Massi MN:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Islam AA:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Lawrence G:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Patellongi I:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Benyamin AF:** Conceptualization, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2020 Sumantri S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Sumantri S, Hatta M, Natzir R *et al.* **Metformin improves FOXP3 mRNA expression through suppression of interferon gamma levels in pristane-induced murine models of lupus [version 1; peer review: 1 approved with reservations]** F1000Research 2020, 9:342 <https://doi.org/10.12688/f1000research.23471.1>

**First published:** 11 May 2020, 9:342 <https://doi.org/10.12688/f1000research.23471.1>

## Introduction

Systemic lupus erythematosus (SLE) is a complex systemic disease, which is defined by multiple organ damage and dysfunction resulting from auto-antibody generation and inherited immune system dysregulation<sup>1</sup>. The complicated pathophysiology and clinical manifestations result in difficulty in reaching an effective and comprehensive management of this condition. Lupus treatment currently relies on immunosuppressants and corticosteroids to suppress the immune system and reduce disease activity. This strategy is not ideal; there are several types of patients who do not respond well to immunosuppression and this therapy also produces side effects, such as recurrent infection, bone density loss, sarcopenia and psychological disturbances. This has led to infection and cardiovascular comorbidity becoming the major cause of mortality related to SLE, and not the disease itself<sup>2</sup>.

Recent studies on experimental models has shown that the key to effective SLE management doesn't rely on suppression of immune system, but how to manage and balance the activity of several key players, such as T regulator (Treg), T autoreactive (Th17), B autoreactive, and B regulator lymphocytes<sup>3</sup>. Inflammatory cytokines and cellular components, such as tumour necrosis factor (TNF)- $\alpha$ , type 1 and 2 interferons, B-lymphocyte stimulator and interleukin-10 has also been known to contribute to the development of auto-antibodies and immune complexes that destroy tissues, especially in the kidneys<sup>4-6</sup>. Recently the activity of interferon (IFN)- $\gamma$  and Th1 cells has been the focus of several experimental and clinical studies, especially its relationship to the development of lupus nephritis and its effect on downstream T-helper cells, such as Treg and Th17<sup>7-9</sup>.

Several studies has also shown the influence of oxidative stress from environmental exposure to the imbalance of Treg and Th1 cells, with subsequent effects on the elevation of IFN $\gamma$  levels and the development of SLE in exposed murine models<sup>10</sup>. Exposure to reactive oxygen species is known to disrupt mitochondrial potential balance and activate the mTOR (mammalian Target of Rapamycin) metabolism regulation pathway by suppressing AMPK (Adenosine Monophosphate Kinase). This in turn results in a preference of Th1 pathway activation rather than Treg<sup>11-13</sup>.

Metformin, an old anti-diabetic drug with a reputable safety profile, recently has been known to be able to regulate the AMPK/mTOR pathway and from several studies has been shown to be able to regulate several autoimmune-, inflammation-, malignant- and aging-related conditions<sup>14,15</sup>. Studies on mice models of rheumatoid arthritis, autoimmune encephalitis and lupus nephritis has also shown this drug's ability as a potential therapy of autoimmune disease<sup>11,16</sup>. This study aims to evaluate the effect of intraperitoneal versus oral metformin in decreasing IFN $\gamma$  and increasing FOXP3 mRNA expression levels on pristane-induced female BALB/c mice, as there no studies that have evaluated the route of metformin delivery, especially on an environmentally induced model of lupus nephritis.

## Methods

### Animal models

In total, 30 female BALB/c mice, aged 6 weeks and weighing approximately 25 grams, were purchased from Universitas Hasanuddin Makassar (Indonesia) and then maintained at the Animal Unit of the Molecular Biology Laboratory of Universitas Hasanuddin Makassar from January 2018. The mice was kept in a temperature controlled housing according to their study group, food and water was provided freely. The number of mice for intervention study was determined using Federer formula for 5 groups. Efforts was made to minimize suffering, such as minimal handling, less frequency of venous sampling, adequate space for living and no other experimentation or pain inducing procedures.

After 2 weeks of acclimatization the mice were then randomly divided into five groups (6 mice/group): group 1, normal control; group 2, SLE model; group 3, normal saline; group 4, oral metformin; and group 5, intraperitoneal metformin groups. Four of the groups (all apart from normal control) were induced with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane; Sigma Aldrich) intraperitoneally. The normal control group was injected with normal saline 0.5 ml intraperitoneally as a control group. After 120 days, groups 1 and 2 were sacrificed using chloroform euthanasia methods (dose of 20 g/m<sup>3</sup> in a closed chamber system). Kidney specimen was then fixed with neutral buffered formalin (NBF) 10%, prepared in paraffin block, sliced to 2 $\mu$ M thickness and then stained with haematoxylin and eosin (H&E).

All intervention, analysis and reporting conducted in this study follows the ARRIVE guidelines for animal studies. Ethical approval for animal studies was obtained from Universitas Hasanuddin's Health Studies Ethical Committee, with protocol number UH17030037. Care and intervention conducted in the research animal, refers to Indonesian National Guidelines on Health Research Ethics and Indonesian Food and Medicine Regulatory Body Guidelines on Good Clinical Practice<sup>17</sup>.

### Intervention

After 120 days, the intervention groups (groups 3–5) were given therapy every morning in the animal laboratory according to their designation: group 3, given 100 mcl normal saline via oral gavage once daily; group 4, given 100 mg/kg body weight of metformin diluted in 100 mcl normal saline via oral gavage once daily; group 5, given 100 mg/kg body weight of metformin diluted in normal saline via intraperitoneal injection once daily. Treatment lasted for 60 days and at the end of the period all three groups were sacrificed, kidney specimen fixed with NBF 10%, prepared in paraffin block and then stained with H&E.

### Cytokine and mRNA expression measurement

Samples for IFN $\gamma$  and FOXP3 mRNA measurements was collected from tail vein sampling (0.1–0.2 ml for each sample). IFN $\gamma$  was measured using the murine IFN $\gamma$  ELISA kit from

Abcam (ab100689) and read using ELISA Reader 270 with 450 nm wavelength (Biomérieux, France).

Total RNA was isolated from using the Qiagen RNeasy Micro Kit (DNA Genotek, Qiagen) according to the manufacturer's instructions. Complementary DNA synthesis was performed by using iScript™ Advanced cDNA Synthesis Kit for RT-qPCR (Bio-Rad). Using cDNA synthesized from 150 ng of total RNA as a template for one amplification, real-time reverse transcriptase (RT)-PCR (CFX Connect system; Bio-Rad) was performed using SYBR® Green PCR Master Mix one step according to the instructions provided (Bio-Rad). Final reaction volume was 20 µL, and included 2 µL cDNA, 10 µL SYBR Green Master Mix, 0.5 µL each of the forward and reverse primers (10 pmol), and 7 µL nuclease-free water. Amplification conditions used for qPCR were: 95°C for 2 minutes, followed by 40 cycles of denaturation and annealing/extension cycles at 95°C for 5 seconds and 60°C for 30 seconds.

The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal control for normalization, GAPDH primer, forward (5'-GAAGGTGAAGGTCGGAGT-3') and reverse (5'-GAAGATGGTATGGGATTTTC-3'). Fold change was determined by the  $\Delta\Delta C_t$  method. All measurements were conducted as per manufacturer's instructions and repeated three times to ensure the validity. Target protein concentration was read as picogram/millilitre and mRNA expression as fold change.

### Histopathological analysis

Kidney specimens were examined by two independent and blinded histopathologists experienced in evaluating murine renal samples. Glomerular scores were evaluated by measuring the level of destruction on 50 glomerular units in each mouse and scored as 0 = normal, 1 = mesangial expansion, 2 = endocapillary proliferation, 3 = capillaritis or necrotic changes and 4 = crescents. Interstitial scoring was measured by evaluating 50 high power fields and scored as 0 = no interstitial involvement, 1 = <25% interstitial involvement, 2 = 25–50% involvement and 3 = >50% involvement<sup>18</sup>.

### Statistical analysis

Statistical analysis (SPSS Statistics ver. 20, IBM) was done by measuring mean difference (t-test) to evaluate the difference in IFN $\gamma$  levels, FOXP3 mRNA fold change and histopathological

scores between the five groups. Correlation analysis was also done to evaluate the relationship between IFN $\gamma$  and FOXP3 mRNA changes to determine the strength of the causality. All tests were reported with 95% confidence interval, standard error and statistical significance score ( $p < 0.05$ ).

### Results

Two female mice expired in the adaptation period; therefore, only 29 mice entered the intervention period and finished the experiments without problems, analysis was done with 5 mice from each group ( $n=25$ ).


Groups 1 and 2 (normal control and SLE model) were sacrificed at the end of the initial 120 day induction period and IFN $\gamma$  and FOXP3 mRNA expression changes are detailed in **Table 1**. The starting level of IFN $\gamma$  shows no difference between normal control and SLE model groups (269.60 vs. 281.12 pg/mL; mean difference 11.52 pg/mL; 95% CI -17.47 – 40.52 pg/mL;  $p=0.386$ ). Post-induction with intraperitoneal pristane (for group 2 only), there was a difference in IFN $\gamma$  levels between normal control and SLE model groups (269.82 vs. 322.42 pg/mL; mean difference 52.59 pg/mL; 95% CI 31.23-73.96 pg/mL;  $p < 0.001$ ) (**Figure 1A**). The expression of FOXP3 mRNA at baseline shows no difference between normal control and SLE model groups (8.87 vs. 8.86-fold change; mean difference -0.00-fold change; 95% CI -0.78-0.77;  $p=0.983$ ), while post-pristane induction there was a mean difference of -1.63-fold change of mRNA FOXP3 expression between groups (8.80 vs. 7.17-fold change; 95% CI -2.17 – 1.09-fold change;  $p < 0.001$ ) (**Figure 1C**).

Groups 3–5 (normal saline, oral metformin and intraperitoneal metformin) entered the 60 days of intervention period. IFN $\gamma$  and FOXP3 mRNA expression changes can be seen in **Table 2**. Comparison between saline control and oral metformin groups resulted in IFN $\gamma$  levels of 309.39 vs. 292.83 pg/mL (mean difference 16.56 pg/mL; 95% CI 0.74-32.37;  $p=0.042$ ; **Figure 1B**). Comparison between saline control and intraperitoneal metformin groups resulted in IFN $\gamma$  levels of 309.39 vs. 266.90 pg/mL (mean difference 42.49 pg/mL; 95% CI 29.24-55.73 pg/mL;  $p < 0.004$ ; **Figure 1B**). Comparison between oral and intraperitoneal metformin groups resulted in IFN $\gamma$  level changes of -33.34 vs. -62.70 pg/mL (mean difference 29.35 pg/mL; 95% CI -52.08 – (-6.63);  $p=0.018$ ; **Figure 1B**).

**Table 1. Comparison of IFN $\gamma$  levels and FOXP3 mRNA expression before and after induction with intraperitoneal pristane.**

Data are presented as mean (95% confidence interval). SLE, systemic lupus erythematosus; PI, post induction.

	IFN $\gamma$ (pg/ml)		Mean difference	p	FOXP3 mRNA (fold change)		Mean difference	p
	Baseline	PI			Baseline	PI		
<b>Normal BALB/c (n=5)</b>	269.60 (254.08-285.12)	269.82 (250.27-289.37)	-0.24 (-24.13-23.68)	0.98	8.87 (8.43-9.31)	8.80 (8.26-9.34)	0.07 (-0.51-0.65)	0.753
<b>SLE model (n=6)</b>	281.12 (249.85-312.39)	322.42 (305.70-339.15)	-42.39 (-83.26-6.66)	0.052	8.86 (8.04-9.69)	7.17 (6.81-7.53)	1.69 (0.63-2.75)	0.011



**Figure 1.** Post pristane induction and post metformin intervention IFN $\gamma$  levels (**A** and **B**) and FOXP3 mRNA expression (**C** and **D**).

**Table 2.** Comparison of IFN $\gamma$  levels and FOXP3 mRNA expression before and after intervention with metformin in pristane-induced BALB/C mice. Data are presented as mean (95% confidence interval). PI, post induction.

	IFN $\gamma$ (pg/ml)		Mean difference	p	FOXP3 mRNA (fold change)		Mean difference	p
	Baseline	PI			Baseline	PI		
<b>Saline control (n=6)</b>	321.54 (303.11-339.97)	309.39 (297.23-321.55)	12.14 (-17.3-41.61)	0.316	7.56 (6.96-8.17)	6.90 (0.09-1.22)	0.66 (0.09-1.22)	0.031
<b>Oral metformin (n=6)</b>	326.18 (310.57-341.78)	292.83 (278.18-307.48)	33.34 (10.74-55.94)	0.015	6.85 (6.37-7.32)	7.79 (7.08-8.51)	-0.94 (-1.53-(-0.35))	0.011
<b>IP metformin (n=6)</b>	329.61 (318.07-341.14)	266.90 (256.58-277.22)	62.70 (47.28-78.12)	<0.001	6.99 (6.34-7.65)	9.02 (8.17-(-1.09))	-2.02 (-2.95-(-1.09))	0.04


FOXP3 mRNA expression changes between saline control compared with oral metformin revealed 6.90 vs. 7.79-fold change (mean difference -0.89-fold change; 95% CI -1.68-(-0.11);  $p=0.03$ ; **Figure 1D**), while between saline control and intraperitoneal metformin there was a 6.90 vs. 9.02-fold change (mean difference -2.12-fold change; 95% CI -2.99-(-1.25);  $p<0.001$ ; **Figure 1D**). Comparison of FOXP3 mRNA expression between oral and intraperitoneal metformin groups was -0.94 vs. (-2.02) fold change (mean difference 1.07-fold change; 95% IC 0.16-1.99;  $p=0.027$ ; **Figure 1D**).

Ratio of FOXP3 mRNA expression and  $IFN\gamma$  levels represents the balance between Treg (anti-inflammatory) and Th1 (pro-inflammatory) activity. Post pristane induction in BALB/c mice showed a ratio of 0.002 vs. 0.003 (mean difference -0.001; 95% CI -0.001 – (-0.0008);  $p<0.001$ ) in SLE model compared to normal BALB/c group (**Figure 2A**). Correlation analysis of FOXP3 mRNA expression and  $IFN\gamma$  level changes between pre and post induction with pristane in the five groups revealed


a Pearson correlation of -0.776 ( $p<0.001$ ) and  $R^2$  value of 0.602 ( $p<0.001$ ) (**Figure 2B**).

Post intervention, comparison between saline control with oral metformin groups was 0.0022 vs. 0.0027 (mean difference -0.0004; 95% CI -0.0007 – (-0.0001);  $p=0.008$ ; **Figure 2C**), while between saline control and intraperitoneal metformin groups was 0.0022 vs. 0.0034 (mean difference -0.001; 95% CI -0.0015 – (-0.0007);  $p<0.001$ ; **Figure 2C**). Comparison between oral and intraperitoneal metformin groups revealed 0.0027 vs. 0.0034 (mean difference -0.0007; 95% CI -0.0011 – (-0.0003);  $p=0.002$ ; **Figure 2C**). Correlation analysis of FOXP3 mRNA expression and  $IFN\gamma$  level changes between post induction and post treatment with metformin revealed a Pearson correlation of -0.785 ( $p=0.001$ ) and  $R^2$  value of 0.616 ( $p=0.001$ ) (**Figure 2D**).

Histopathological analysis on kidney specimens resulted in a variable change in each intervention group (**Figure 3**). Glomerular scoring comparison between BALB/c normal



**Figure 2.** Post pristane induction FOXP3 mRNA/IFN-gamma ratio and correlation scatter plot (**A** and **B**) and post metformin therapy FOXP3 mRNA/IFN-gamma ratio and correlation scatter plot (**C** and **D**).



**Figure 3. Kidney of BALB/c mice stained with hematoxylin and eosin, before intervention.** Analysis on normal BALB/c control kidney (upper and lower left) revealed mild tubulo-nephritis changes, with minimal mesangial expansion, endocapillary proliferation and capillaritis. Significant interstitial infiltration (25–50% field) only happens in one member of normal BALB/c group. In the SLE model group (upper and lower right), after induction with pristane, there was a significant change in the glomeruli, with dominant endocapillary proliferation and minimal mesangial expansion and capillaritis.

and SLE model groups revealed a score of 2.2 vs. 3.0 (mean difference 0.80; 95% CI 0.33-1.26;  $p=0.04$ ). Interstitial scoring comparison between BALB/c normal and SLE model groups revealed a score of 1.20 vs. 1.40 (mean difference 0.20; 95% CI 0.83-1.23;  $p=0.667$ ). Total histopathological scoring between the two groups revealed a score of 4.40 vs. 3.40 (mean difference 1.00; 95% CI -0.08 – 2.08;  $p=0.066$ ).


Histopathological scoring between intervention groups (normal saline, oral and intraperitoneal metformin) did not reveal significant differences, although qualitative analysis by blinded pathologists revealed difference in the degree of nephritis occurring in each group (Figure 4).

## Discussion

SLE is a multifactorial inflammatory autoimmune disease, with clinical manifestations that involves various tissues and organs. The aetiology of this autoimmune condition is linked to dysfunctional B and T lymphocyte responses to environmental stimulus in a genetically susceptible individual, which in turn determines the immune response to various autoantigens and can cause tissue damage. The application of pristane, an aromatic hydrocarbon, has an advantage to genetically modified

mice, because the ability of this model to mimic SLE in humans, which in a genetically susceptible individual is usually caused by environmental exposure. Pristane mouse models also enables researchers to evaluate pathophysiological changes in a timely manner, and to give a picture of the cellular mechanism involved in the development and progressivity of SLE<sup>12</sup>.

In this study, we showed that after induction with pristane, there was a significant difference in the level of IFN $\gamma$  in the normal BALB/c group compared to the SLE model (269.82 vs. 322.42 pg/mL; mean difference 52.59; 95% CI 31.23 - 73.96;  $p<0.001$ ). Richards *et al.*<sup>12</sup> showed that IFN $\gamma$  is an important component in the development of lupus nephritis in pristane-induced murine models. Induction with pristane in an IFN $\gamma$  deficient mouse (IFN $\gamma$ <sup>-/-</sup>) would not result in a change of renal pathology corresponding to lupus nephritis. Furthermore, in this model of IFN $\gamma$  deficient mice, post pristane induction, no antibodies characteristically associated with lupus, such as IgG anti-ssDNA and anti-chromatin antibody, were found<sup>12,19</sup>. Chiche *et al.*<sup>19</sup> also noted that the activity of pathways related to IFN $\gamma$  play an important role in the development of anti-dsDNA antibodies and the reduction of lymphocyte counts in patients with SLE.



**Figure 4. Kidney of BALB/c mice stained with hematoxylin and eosin, after intervention.** In general, there was a widespread and significant glomerular and interstitial change across all groups, consistent with previous SLE models. Tubulo-nephritic changes significantly happens more than glomerulo-nephritis, although significant interstitial infiltration only happens in the normal saline group (upper right), especially in two members of its group. Qualitatively, two blinded pathologists concluded that the most severe changes happen in the normal saline group and the least severe in the intraperitoneal metformin group.

Regarding the expression of FOXP3 mRNA, we showed that there was a significant difference between normal BALB/c compared to the SLE model group (8.80 vs. 7.17-fold change; mean difference -1.63; 95% CI 2.17 – 1.09;  $p < 0.001$ ). The expression of FOXP3 mRNA in pristane induced murine models is a marker for Treg cell activity. In a study by Peixoto *et al.*, it was shown that on day 90 and 120 post induction there was a decrease in CD4+CD25+FOXP3+ (Treg) cell count in peripheral blood samples<sup>20</sup>. These authors also showed that the reduction in Treg count was correlated with an increase in IFN $\gamma$  ( $p = 0.017$ ), TNF $\alpha$  ( $p = 0.043$ ) and TGF- $\beta$ 1 ( $p = 0.038$ ). Furthermore, Kluger *et al.* also pointed out that the disturbances in Treg (FOXP3+) function contributes to the development of acute glomerulonephritis in pristane induced lupus<sup>21</sup>.

In this study, metformin intervention, whether in oral form (309.39 vs. 292.83 pg/ml; mean difference 16.56; 95% CI 0.74-32.37;  $p = 0.042$ ) or intraperitoneal injection (309.39 vs. 266.90 pg/ml; mean difference 42.49 pg/ml; 95% CI 29.24-55.73;  $p < 0.001$ ) gave a significantly superior suppression of IFN $\gamma$  levels. A previous study by Mardani *et al.* showed that an intervention with probiotics could reduce IFN $\gamma$  and IL-17 levels in pristane induced murine lupus, followed by a reduction in autoantibodies such as ANA, anti-dsDNA and anti-RNP<sup>9</sup>.

Reduction of IFN $\gamma$  levels could improve the outcome of lupus nephritis by inactivating B7/CD28 signalling pathway, which results in a reduction in ANA autoantibodies, IL-4 and IFN $\gamma$  levels. The inactivation of B7/CD28 pathways also caused anergy, tolerance and apoptosis of T-cells, which results in a decrease of urine protein and immune complex deposition in the kidneys of pristane induced C57BL/6J mice<sup>22</sup>.

This study revealed that the administration of oral and intraperitoneal metformin gave a significantly better suppression of IFN $\gamma$  than placebo, in accordance to the study conducted by Yin *et al.*<sup>23</sup>. In that study, intervention with metformin and 2-DG (2-deoxy-glucose) in B6.Sle1Sle2.Sle3 mice resulted in a suppression of IL-17 and IFN $\gamma$  levels through a blockade on the glucose oxidation pathway. This blockade on the glucose oxidation pathway also normalized T-cell metabolism, which in turn suppresses the activation of CD4+ T-cells and returns the balance of pro/anti-inflammatory cytokines in mice models<sup>10</sup>.

Regarding FOXP3 mRNA expression, this study showed that intervention with metformin via oral (6.90 vs. 7.79-fold change; mean difference -0.89; 95% CI -1.68 – (-0.11);  $p = 0.03$ ) or intraperitoneal route (6.90 vs. 9.02-fold change; 95% CI -2.99 – (-1.25);  $p < 0.001$ ) gave a significantly superior increase

in FOXP3 mRNA expression compared to saline control. We also showed that there was a strong significant inverse correlation between the increase of FOXP3 mRNA expression and decrease of IFN $\gamma$  resulting from metformin intervention ( $R=-0.785$ ;  $p=0.001$ ). Furthermore, it seems that the reduction of IFN $\gamma$  explains the increase in FOXP3 mRNA expression rather strongly, as shown by the  $R^2$  value of 0.616 ( $p=0.001$ ). The above result was consistent with several studies in pristane induced models; a decrease in FOXP3+ T-cells and increase in CD4+CD69+ T-cells coincide with an increase in IFN $\gamma$  levels in intraperitoneal fluid<sup>20,23</sup>.

To the best of our knowledge, this is the first study that evaluates the effect of metformin on the expression of FOXP3 mRNA in lupus, although it is also known that metformin has the ability to induce AMPK pathway activity and suppress mTOR signalling<sup>24,25</sup>. Metformin has also been known to be able to improve disease activity index, histological and inflammatory profiles in several other autoimmune models, such as inflammatory bowel disease<sup>26</sup> and autoimmune insulinitis<sup>14</sup> through the modulation of AMPK-mTOR pathway and the resulting changes in IL-17, IFN $\gamma$ , IL-10 and FOXP3 associated cytokines and cells.

Intraperitoneal route of metformin gave a superior effect on the suppression of IFN $\gamma$  levels and increasing FOXP3 mRNA expression compared to the oral route, and to the best of our knowledge this was the first study that observed this effect in pristane induced murine model of lupus. A study by Dowling *et al.* on NOD/SCID mice revealed that plasma levels of metformin were higher via intraperitoneal than oral route (145  $\mu$ M vs. 77  $\mu$ M; range 65.8-214.7  $\mu$ M vs. 41.6-99.0  $\mu$ M)<sup>27</sup>. Thus it is concluded that intraperitoneal metformin gave a higher suppression of IFN $\gamma$  and increase of FOXP3 mRNA expression through an plasma level rather than an oral route. In addition, a study by Wang *et al.* in a scleroderma model has also shown the ability of intraperitoneal metformin to dose dependently reduce IL-17A levels and ROR $\gamma$ t expression and increase FOXP3 mRNA expression<sup>28</sup>.

Although this study was able to prove that there was a characteristic change in accordance to lupus nephritis in pristane induced models compared to normal BALB/c, subsequent therapy with metformin failed to produce a statistically significant score change. However, qualitative analysis by blinded pathologists has confirmed that there was at least a difference in renal changes that showed better results in intraperitoneally treated mice compared with oral metformin and placebo control. This result could be caused by a short period of intervention;

a longer treatment time could possibly result in a significant difference in renal scoring.

### Limitations

We did not perform an evaluation of autoantibodies related to SLE, such as anti-dsDNA, anti-Sm and anti-RNP1. However, several murine studies has confirmed the ability of pristane induced BALB/c in producing related auto-antibodies<sup>29,30</sup>. Our research also did not evaluate the antibody response to metformin therapy; however several studies has shown the ability of metformin in reducing autoantibodies related to SLE<sup>10,22</sup>. We also did not evaluate the expression of mRNAs related to IFN $\gamma$ , but several studies has shown that Th1 activity is closely related to IFN $\gamma$  levels<sup>8,31,32</sup>. Furthermore it has been recently suggested that the cytokine balance could play an important role in determining active T-cell subsets, changing the phenotype of peripheral T-cells and contributes to the pathogenesis of lupus<sup>13,33</sup>.

### Conclusions

A murine model of SLE by pristane induced female BALB/c mice could be used to represent a model of lupus similar to the human condition. The increased activity of Th1 and reduced activity of Treg, in this study represented by pro-inflammatory IFN $\gamma$  levels and FOXP3 mRNA expression, has proven to be related to the development of lupus nephritis. Metformin is a potential new therapy to reduce the levels of IFN $\gamma$  and increase FOXP3 mRNA expression in SLE and in turn inhibits the development of glomerulonephritis. Intraperitoneal metformin, intravenous in humans, could provide a novel route of administration to improve the effect of metformin on lupus patients.

### Data availability

#### Underlying data

Open Science Framework: Metformin on Pristane Induced Lupus, <https://doi.org/10.17605/OSF.IO/S9GRP><sup>34</sup>.

This project contains the following underlying data:

- IFN $\gamma$  levels for all mice pre and post intervention;
- FOXP3 expression fold change for all mice pre and post intervention;
- Interstitial and glomerular scoring for all mice; and
- Uncropped, unedited kidney images for all mice.

Data are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

## References

1. Crispin JC, Lioussis SN, Kis-Toth K, *et al.*: **Pathogenesis of human systemic lupus erythematosus: recent advances.** *Trends Mol Med.* 2010; 16(2): 47–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Lateef A, Petri M: **Unmet medical needs in systemic lupus erythematosus.** *Arthritis Res Ther.* 2012; 14(Suppl 4): S4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Dolf S, Bijl M, Huitema MG, *et al.*: **Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus.** *Clin Immunol.* 2011; 141(2): 197–204. [PubMed Abstract](#) | [Publisher Full Text](#)
4. George B, Ricard C, Boumpas DT: **Systemic Lupus Erythematosus: Pathogenesis and Clinical Features.** *Eular On-line Course Rheum Dis.*

2012;(1909): 476–505.

**Reference Source**

5. Finzel S, Schaffer S, Rizzi M, *et al.*: **Pathogenesis of systemic lupus erythematosus.** *Z Rheumatol.* 2018; **77**(9): 789–98.  
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Mok CC, Lau CS: **Pathogenesis of systemic lupus erythematosus.** *J Clin Pathol.* 2003; **56**(7): 481–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Lech M, Anders HJ: **The pathogenesis of lupus nephritis.** *J Am Soc Nephrol.* 2013; **24**(9): 1357–66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Viillard JF, Pellegrin JL, Ranchin V, *et al.*: **Th1 (IL-2, interferon-gamma (IFN-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).** *Clin Exp Immunol.* 1999; **115**(1): 189–95.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Mardani F, Mahmoudi M, Esmaili SA, *et al.*: **In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic *Lactobacillus* probiotics.** *J Cell Physiol.* 2018; **234**(1): 642–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Yin Y, Choi SC, Xu Z, *et al.*: **Normalization of CD4<sup>+</sup> T cell metabolism reverses lupus.** *Sci Transl Med.* 2015; **7**(274).  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Nath N, Khan M, Paintlia MK, *et al.*: **Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis.** *J Immunol.* 2009; **182**(12): 8005–14.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Richards HB, Satoh M, Jennette JC, *et al.*: **Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane.** *Kidney Int.* 2001; **60**(6): 2173–80.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Talaat RM, Mohamed SF, Bassyouni IH, *et al.*: **Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.** *Cytokine.* 2015; **72**(2): 146–53.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Duan W, Ding Y, Yu X, *et al.*: **Metformin mitigates autoimmune insulinitis by inhibiting Th1 and Th17 responses while promoting Treg production.** *Am J Transl Res.* 2019; **11**(4): 2393–402.  
[PubMed Abstract](#) | [Free Full Text](#)
15. Rena G, Hardie DG, Pearson ER: **The mechanisms of action of metformin.** *Diabetologia.* 2017; **60**(9): 1577–85.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Son HJ, Lee J, Lee SY, *et al.*: **Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis.** *Mediators Inflamm.* 2014; **2014**: 973986.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. KNEPK: **Pedoman Nasional Etik Penelitian Kesehatan 2011.** *Litbang Kementerian Kesehatan.* 2011.  
**Reference Source**
18. Bossaller L, Christ A, Pelka K, *et al.*: **TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.** *J Immunol.* 2016; **197**(4): 1044–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Peng SL, Moslehi J, Craft J: **Roles of interferon-gamma and interleukin-4 in murine lupus.** *J Clin Invest.* 1997; **99**(8): 1936–46.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Peixoto TV, Carrasco S, Botte DAC, *et al.*: **CD4<sup>+</sup>CD69<sup>+</sup> T cells and CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.** *Adv Rheumatol.* (London, England). 2019; **59**(1): 30.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Kluger MA, Nosko A, Ramcke T, *et al.*: **RORγt expression in T<sub>reg</sub> promotes systemic lupus erythematosus via IL-17 secretion, alteration of T<sub>reg</sub> phenotype and suppression of Th2 responses.** *Clin Exp Immunol.* 2017; **188**(1): 63–78.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Huang L, Kong Y, Wang J, *et al.*: **Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.** *Mol Med Rep.* 2015; **12**(3): 4187–95.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Fu D, Senouthai S, Wang J, *et al.*: **Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance.** *BMC Nephrol.* 2019; **20**(1): 350.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Chung MM, Nicol CJ, Cheng YC, *et al.*: **Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs.** *Exp Cell Res.* 2017; **352**(1): 75–83.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Howell JJ, Hellberg K, Turner M, *et al.*: **Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.** *Cell Metab.* 2017; **25**(2): 463–71.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Lee SY, Lee SH, Yang EJ, *et al.*: **Metformin ameliorates inflammatory bowel disease by suppression of the stat3 signaling pathway and regulation of the between Th17/Treg Balance.** *PLoS One.* 2015; **10**(9): e0135858.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Dowling RJ, Lam S, Bassi C, *et al.*: **Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy.** *Cell Metab.* 2016; **23**(4): 567–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Wang Y, Zhang S, Liang Z, *et al.*: **Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation.** *Mol Immunol.* 2019; **114**: 72–80.  
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Richards HB, Satoh M, Shaw M, *et al.*: **Interleukin 6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus.** *J Exp Med.* 1998; **188**(5): 985–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Satoh M, Richards HB, Shaheen VM, *et al.*: **Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane.** *Clin Exp Immunol.* 2000; **121**(2): 399–405.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Balomenos D, Rumold R, Theofilopoulos AN: **Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-*lpr* mice.** *J Clin Invest.* 1998; **101**(2): 364–71.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Luzina IG, Keegan AD, Heller NM, *et al.*: **Regulation of inflammation by interleukin-4: a review of “alternatives.”** *J Leukoc Biol.* 2012; **92**(4): 753–64.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Guimarães PM, Scavuzzi BM, Stadtlober NP, *et al.*: **Cytokines in systemic lupus erythematosus: Far beyond Th1/Th2 dualism lupus: Cytokine profiles.** *Immunol Cell Biol.* 2017; **95**(9): 824–831.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Sumantri S: **Metformin on Pristane Induced Lupus.** 2020;. <http://www.doi.org/10.17605/OSF.IO/S9GRP>

# Open Peer Review

Current Peer Review Status: ?

---

Version 1

Reviewer Report 26 May 2020

<https://doi.org/10.5256/f1000research.25902.r63253>

© 2020 Ye S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Shuang Ye**

Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiaotong University School of Medicine, Shanghai, China

The authors tried to illustrate the effect of metformin on pristane-induced mice in terms of IFN- $\gamma$  levels and FOXP3 mRNA expression. However, the authors did not see the significant difference of renal histopathological score between intervention groups. It is better to provide evidence of effect of metformin on other manifestations, i.e. serological, in this model. The conclusion of "intravenous administration in human, could provide a novel route of administration...." could not be drawn from the data provided in the manuscript.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Partly

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Our group carried out proof-of-concept trial and randomised placebo-controlled trial of metformin in lupus patients.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 26 May 2020

**Stevent Sumantri**, Universitas Pelita Harapan, Tangerang, Indonesia

Dear Dr Shuang Ye,

Many thanks for your review on the research article. Could you kindly advise in which way we could further improve the quality of this article?

Regards,  
Stevent Sumantri MD

**Competing Interests:** No competing interests were disclosed.

Reviewer Response 07 Jun 2020

**shuang ye**, Shanghai Jiaotong University School of Medicine, Shanghai, China

1. The authors did not see the positive results of renal histopathology between intervention groups. We suggest to provide evidence of other manifestations, such as autoantibodies, in this model.
2. The conclusion of "intravenous administration in human, could provide a novel route of administration...." could not be drawn from the data provided in the manuscript, and should be deleted.

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

**F1000Research**